Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: Identification of lupus anticoagulants

Bahaa S. Malaeb, Thomas Gardner, Vitaly Margulis, Ling Yang, Jay Y. Gillenwater, Leland W K Chung, Gail Macik, Kenneth S. Koeneman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives. To evaluate the cause and significance of elevated activated partial thromboplastin time (aPTT) in a group of patients who received a first-generation adenoviral vector (Ad-OC-TK) delivering a toxic gene to prostate cancer cells as part of a Phase I clinical trial at the University of Virginia. Methods. Eleven subjects were injected intratumorally to metastatic lesions of prostate cancer in the prostatic fossa, retroperitoneal lymph nodes, or bone (iliac, ischium, or vertebrae). After the initial laboratory evaluation, patients with elevated aPTT underwent a series of additional tests, including mixing studies, coagulation factor, prekallikrein, and high-molecular-weight kininogen, and lupus anticoagulant studies (modified Russell viper venom time) with phospholipid correction, and a Staclot LA assay. Results. Of the 11 subjects who were enrolled in the trial, 6 had elevated aPTT values. Of the 6 patients, 3 had aPTT elevation of more than 10 seconds above normal. Two of the subjects with higher values demonstrated an inhibitory pattern with the factor VIII and XI assays, and the lupus anticoagulant studies were positive. No clinical sequelae to the elevated aPTT values were observed. Conclusions. This is, to our knowledge, the first formal report of a first-generation adenoviral vector causing a slight transient elevation of the aPTT through the induction of an antiphospholipid antibody. No clinical sequelae related to elevated aPTT values were observed. The adenoviral protocol was safe; similar protocols should be aware of this phenomenon.

Original languageEnglish (US)
Pages (from-to)830-834
Number of pages5
JournalUrology
Volume66
Issue number4
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Lupus Coagulation Inhibitor
Partial Thromboplastin Time
Genetic Therapy
Prostatic Neoplasms
Ischium
High Molecular Weight Kininogens
Factor XI
Prekallikrein
Clinical Trials, Phase I
Antiphospholipid Antibodies
Blood Coagulation Factors
Poisons
Prothrombin Time
Factor VIII
Phospholipids
Spine
Lymph Nodes
Bone and Bones
Genes

ASJC Scopus subject areas

  • Urology

Cite this

Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer : Identification of lupus anticoagulants. / Malaeb, Bahaa S.; Gardner, Thomas; Margulis, Vitaly; Yang, Ling; Gillenwater, Jay Y.; Chung, Leland W K; Macik, Gail; Koeneman, Kenneth S.

In: Urology, Vol. 66, No. 4, 10.2005, p. 830-834.

Research output: Contribution to journalArticle

Malaeb, Bahaa S. ; Gardner, Thomas ; Margulis, Vitaly ; Yang, Ling ; Gillenwater, Jay Y. ; Chung, Leland W K ; Macik, Gail ; Koeneman, Kenneth S. / Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer : Identification of lupus anticoagulants. In: Urology. 2005 ; Vol. 66, No. 4. pp. 830-834.
@article{7d28bd648ef34fc780a0d5a9cff5d16e,
title = "Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: Identification of lupus anticoagulants",
abstract = "Objectives. To evaluate the cause and significance of elevated activated partial thromboplastin time (aPTT) in a group of patients who received a first-generation adenoviral vector (Ad-OC-TK) delivering a toxic gene to prostate cancer cells as part of a Phase I clinical trial at the University of Virginia. Methods. Eleven subjects were injected intratumorally to metastatic lesions of prostate cancer in the prostatic fossa, retroperitoneal lymph nodes, or bone (iliac, ischium, or vertebrae). After the initial laboratory evaluation, patients with elevated aPTT underwent a series of additional tests, including mixing studies, coagulation factor, prekallikrein, and high-molecular-weight kininogen, and lupus anticoagulant studies (modified Russell viper venom time) with phospholipid correction, and a Staclot LA assay. Results. Of the 11 subjects who were enrolled in the trial, 6 had elevated aPTT values. Of the 6 patients, 3 had aPTT elevation of more than 10 seconds above normal. Two of the subjects with higher values demonstrated an inhibitory pattern with the factor VIII and XI assays, and the lupus anticoagulant studies were positive. No clinical sequelae to the elevated aPTT values were observed. Conclusions. This is, to our knowledge, the first formal report of a first-generation adenoviral vector causing a slight transient elevation of the aPTT through the induction of an antiphospholipid antibody. No clinical sequelae related to elevated aPTT values were observed. The adenoviral protocol was safe; similar protocols should be aware of this phenomenon.",
author = "Malaeb, {Bahaa S.} and Thomas Gardner and Vitaly Margulis and Ling Yang and Gillenwater, {Jay Y.} and Chung, {Leland W K} and Gail Macik and Koeneman, {Kenneth S.}",
year = "2005",
month = "10",
doi = "10.1016/j.urology.2005.04.041",
language = "English (US)",
volume = "66",
pages = "830--834",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer

T2 - Identification of lupus anticoagulants

AU - Malaeb, Bahaa S.

AU - Gardner, Thomas

AU - Margulis, Vitaly

AU - Yang, Ling

AU - Gillenwater, Jay Y.

AU - Chung, Leland W K

AU - Macik, Gail

AU - Koeneman, Kenneth S.

PY - 2005/10

Y1 - 2005/10

N2 - Objectives. To evaluate the cause and significance of elevated activated partial thromboplastin time (aPTT) in a group of patients who received a first-generation adenoviral vector (Ad-OC-TK) delivering a toxic gene to prostate cancer cells as part of a Phase I clinical trial at the University of Virginia. Methods. Eleven subjects were injected intratumorally to metastatic lesions of prostate cancer in the prostatic fossa, retroperitoneal lymph nodes, or bone (iliac, ischium, or vertebrae). After the initial laboratory evaluation, patients with elevated aPTT underwent a series of additional tests, including mixing studies, coagulation factor, prekallikrein, and high-molecular-weight kininogen, and lupus anticoagulant studies (modified Russell viper venom time) with phospholipid correction, and a Staclot LA assay. Results. Of the 11 subjects who were enrolled in the trial, 6 had elevated aPTT values. Of the 6 patients, 3 had aPTT elevation of more than 10 seconds above normal. Two of the subjects with higher values demonstrated an inhibitory pattern with the factor VIII and XI assays, and the lupus anticoagulant studies were positive. No clinical sequelae to the elevated aPTT values were observed. Conclusions. This is, to our knowledge, the first formal report of a first-generation adenoviral vector causing a slight transient elevation of the aPTT through the induction of an antiphospholipid antibody. No clinical sequelae related to elevated aPTT values were observed. The adenoviral protocol was safe; similar protocols should be aware of this phenomenon.

AB - Objectives. To evaluate the cause and significance of elevated activated partial thromboplastin time (aPTT) in a group of patients who received a first-generation adenoviral vector (Ad-OC-TK) delivering a toxic gene to prostate cancer cells as part of a Phase I clinical trial at the University of Virginia. Methods. Eleven subjects were injected intratumorally to metastatic lesions of prostate cancer in the prostatic fossa, retroperitoneal lymph nodes, or bone (iliac, ischium, or vertebrae). After the initial laboratory evaluation, patients with elevated aPTT underwent a series of additional tests, including mixing studies, coagulation factor, prekallikrein, and high-molecular-weight kininogen, and lupus anticoagulant studies (modified Russell viper venom time) with phospholipid correction, and a Staclot LA assay. Results. Of the 11 subjects who were enrolled in the trial, 6 had elevated aPTT values. Of the 6 patients, 3 had aPTT elevation of more than 10 seconds above normal. Two of the subjects with higher values demonstrated an inhibitory pattern with the factor VIII and XI assays, and the lupus anticoagulant studies were positive. No clinical sequelae to the elevated aPTT values were observed. Conclusions. This is, to our knowledge, the first formal report of a first-generation adenoviral vector causing a slight transient elevation of the aPTT through the induction of an antiphospholipid antibody. No clinical sequelae related to elevated aPTT values were observed. The adenoviral protocol was safe; similar protocols should be aware of this phenomenon.

UR - http://www.scopus.com/inward/record.url?scp=26644466325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26644466325&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.04.041

DO - 10.1016/j.urology.2005.04.041

M3 - Article

C2 - 16230147

AN - SCOPUS:26644466325

VL - 66

SP - 830

EP - 834

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -